{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T06:19:55Z","timestamp":1764829195856,"version":"build-2065373602"},"reference-count":64,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T00:00:00Z","timestamp":1710979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology Reports"],"abstract":"<jats:p>Non-Hodgkin\u2019s lymphomas (NHLs) are a heterogeneous group of lymphoproliferative disorders originating from B, T, or NK lymphocytes. They represent approximately 4\u20135% of new cancer cases and are classified according to the revised WHO system based on cell lineage, morphology, immunophenotype, and genetics. Diagnosis requires adequate biopsy material, though integrated approaches are used for leukemic presentations. Molecular profiling is improving classification and identifying prognostic markers. Indolent NHLs, such as follicular lymphoma and marginal zone lymphoma, typically pursue a non-aggressive clinical course with long survival. Aggressive diffuse large B-cell lymphoma (DLBCL) is the most common subtype. Recent studies have elucidated pathogenic mechanisms like MYC translocations and BCR pathway mutations. \u201cDouble hit\u201d lymphomas with MYC and BCL2\/BCL6 alterations confer a poor prognosis. Treatment approaches are evolving, with chemoimmunotherapy remaining standard for many indolent cases while intensified regimens and targeted agents show promise for refractory or high-risk aggressive disease. Continued elucidation of the genetic and microenvironmental underpinnings of lymphomagenesis is critical for developing personalized therapeutic strategies.<\/jats:p>","DOI":"10.3390\/hematolrep16010017","type":"journal-article","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T06:35:30Z","timestamp":1711002930000},"page":"164-178","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Navigating Lymphomas through BCR Signaling and Double-Hit Insights: Overview"],"prefix":"10.3390","volume":"16","author":[{"given":"Antonella","family":"Argentiero","sequence":"first","affiliation":[{"name":"Istituto Tumori \u201cGiovanni Paolo II\u201d, Istituto di Ricovero e Cura a Carattere Scientifico, 70124 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Andriano","sequence":"additional","affiliation":[{"name":"Pharmacology Section, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari Aldo Moro Medical School, 70124 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donatello","family":"Marziliano","sequence":"additional","affiliation":[{"name":"Unit of Internal Medicine \u201cG. Baccelli\u201d, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari Aldo Moro Medical School, 70124 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1942-2601","authenticated-orcid":false,"given":"Vanessa","family":"Desantis","sequence":"additional","affiliation":[{"name":"Pharmacology Section, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari Aldo Moro Medical School, 70124 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3322\/CA.2007.0010","article-title":"Cancer Statistics, 2008. CA","volume":"58","author":"Jemal","year":"2008","journal-title":"Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 Revision of the World Health Organization Classification of Lymphoid Neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"ref_3","first-page":"1338","article-title":"Clinical Utility of Recently Identified Diagnostic, Prognostic, and Predictive Molecular Biomarkers in Mature B-Cell Neoplasms","volume":"30","author":"Onaindia","year":"2017","journal-title":"Mod. Pathol. Off. J. U. S. Can. Acad. Pathol. Inc."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016 US Lymphoid Malignancy Statistics by World Health Organization Subtypes. CA","volume":"66","author":"Teras","year":"2016","journal-title":"Cancer J. Clin."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1038\/bjc.2015.94","article-title":"Lymphoma Incidence, Survival and Prevalence 2004-2014: Sub-Type Analyses from the UK\u2019s Haematological Malignancy Research Network","volume":"112","author":"Smith","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/leu.2014.251","article-title":"Follicular Lymphoma in Sweden: Nationwide Improved Survival in the Rituximab Era, Particularly in Elderly Women: A Swedish Lymphoma Registry Study","volume":"29","author":"Peterson","year":"2015","journal-title":"Leukemia"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/0140-6736(92)90280-G","article-title":"High Incidence of Primary Gastric Lymphoma in Northeastern Italy","volume":"339","author":"Doglioni","year":"1992","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1349-7006.2004.tb03256.x","article-title":"Effect of Hepatitis C Virus Infection on the Risk of Non-Hodgkin\u2019s Lymphoma: A Meta-Analysis of Epidemiological Studies","volume":"95","author":"Matsuo","year":"2004","journal-title":"Cancer Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1200\/JCO.2011.41.4466","article-title":"Chlamydophila Psittaci Eradication with Doxycycline as First-Line Targeted Therapy for Ocular Adnexae Lymphoma: Final Results of an International Phase II Trial","volume":"30","author":"Ferreri","year":"2012","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.leukres.2015.11.001","article-title":"Targeting B-Cell Non Hodgkin Lymphoma: New and Old Tricks","volume":"42","author":"Solimando","year":"2016","journal-title":"Leuk. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton\u2019s Tyrosine Kinase in B Cells and Malignancies","volume":"17","author":"Dammeijer","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1200710","article-title":"MYD88 L265P Somatic Mutation in Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"367","author":"Treon","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1056\/NEJMoa1014209","article-title":"BRAF Mutations in Hairy-Cell Leukemia","volume":"364","author":"Tiacci","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Rao, L., Giannico, D., Leone, P., Solimando, A.G., Maiorano, E., Caporusso, C., Duda, L., Tamma, R., Mallamaci, R., and Susca, N. (2020). HB-EGF-EGFR Signaling in Bone Marrow Endothelial Cells Mediates Angiogenesis Associated with Multiple Myeloma. Cancers, 12.","DOI":"10.3390\/cancers12010173"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Di Lernia, G., Leone, P., Solimando, A.G., Buonavoglia, A., Saltarella, I., Ria, R., Ditonno, P., Silvestris, N., Crudele, L., and Vacca, A. (2020). Bortezomib Treatment Modulates Autophagy in Multiple Myeloma. J. Clin. Med., 9.","DOI":"10.3390\/jcm9020552"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells","volume":"351","author":"Dave","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3324\/haematol.2015.139493","article-title":"Role of the Tumor Microenvironment in Mature B-Cell Lymphoid Malignancies","volume":"101","author":"Fowler","year":"2016","journal-title":"Haematologica"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.cancergen.2023.01.003","article-title":"A t(4;13)(Q21;Q14) Translocation in B-Cell Chronic Lymphocytic Leukemia Causing Concomitant Homozygous DLEU2\/miR15a\/miR16-1 and Heterozygous ARHGAP24 Deletions","volume":"272\u2013273","author":"Tolomeo","year":"2023","journal-title":"Cancer Genet."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1182\/blood-2012-09-454355","article-title":"MYD88 L265P in Waldenstr\u00f6m Macroglobulinemia, Immunoglobulin M Monoclonal Gammopathy, and Other B-Cell Lymphoproliferative Disorders Using Conventional and Quantitative Allele-Specific Polymerase Chain Reaction","volume":"121","author":"Xu","year":"2013","journal-title":"Blood"},{"key":"ref_20","first-page":"2615","article-title":"Targeting the Immune Microenvironment in Waldenstr\u00f6m Macroglobulinemia via Halting the CD40\/CD40-Ligand Axis","volume":"141","author":"Sacco","year":"2023","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.3109\/10428194.2016.1173212","article-title":"Genetic Aberrations in Small B-Cell Lymphomas and Leukemias: Molecular Pathology, Clinical Relevance and Therapeutic Targets","volume":"57","author":"Bogusz","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1182\/asheducation-2013.1.103","article-title":"Human Herpesvirus-8: Kaposi Sarcoma, Multicentric Castleman Disease, and Primary Effusion Lymphoma","volume":"2013","author":"Kaplan","year":"2013","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1158\/0008-5472.CAN-19-1493","article-title":"Lymphoma Angiogenesis Is Orchestrated by Noncanonical Signaling Pathways","volume":"80","author":"Gloger","year":"2020","journal-title":"Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1182\/blood-2003-05-1383","article-title":"VH Mutation Status and VDJ Rearrangement Structure in Mantle Cell Lymphoma: Correlation with Genomic Aberrations, Clinical Characteristics, and Outcome","volume":"102","author":"Kienle","year":"2003","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1038\/leu.2012.72","article-title":"Non-Nodal Type of Mantle Cell Lymphoma Is a Specific Biological and Clinical Subgroup of the Disease","volume":"26","author":"Royo","year":"2012","journal-title":"Leukemia"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3324\/haematol.2017.177162","article-title":"Inhibition of Focal Adhesion Kinase Overcomes Resistance of Mantle Cell Lymphoma to Ibrutinib in the Bone Marrow Microenvironment","volume":"103","author":"Rudelius","year":"2018","journal-title":"Haematologica"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ccr.2013.04.011","article-title":"EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation","volume":"23","author":"Popovic","year":"2013","journal-title":"Cancer Cell"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"12420","DOI":"10.1073\/pnas.1305656110","article-title":"PTEN Loss Defines a PI3K\/AKT Pathway-Dependent Germinal Center Subtype of Diffuse Large B-Cell Lymphoma","volume":"110","author":"Pfeifer","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic Active B-Cell-Receptor Signalling in Diffuse Large B-Cell Lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature09730","article-title":"Inactivating Mutations of Acetyltransferase Genes in B-Cell Lymphoma","volume":"471","author":"Pasqualucci","year":"2011","journal-title":"Nature"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1182\/blood-2007-02-072082","article-title":"Mutations in the DNA-Binding Codons of TP53, Which Are Associated with Decreased Expression of TRAILreceptor-2, Predict for Poor Survival in Diffuse Large B-Cell Lymphoma","volume":"110","author":"Young","year":"2007","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1182\/blood-2012-05-433334","article-title":"Mutational Profile and Prognostic Significance of TP53 in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP: Report from an International DLBCL Rituximab-CHOP Consortium Program Study","volume":"120","author":"Wu","year":"2012","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"18250","DOI":"10.1073\/pnas.1314608110","article-title":"Landscape of Somatic Mutations and Clonal Evolution in Mantle Cell Lymphoma","volume":"110","author":"Navarro","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4599","DOI":"10.1182\/blood-2006-08-039859","article-title":"Point Mutations and Genomic Deletions in CCND1 Create Stable Truncated Cyclin D1 mRNAs That Are Associated with Increased Proliferation Rate and Shorter Survival","volume":"109","author":"Wiestner","year":"2007","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"73558","DOI":"10.18632\/oncotarget.12434","article-title":"CCND1 Mutations Increase Protein Stability and Promote Ibrutinib Resistance in Mantle Cell Lymphoma","volume":"7","author":"Mohanty","year":"2016","journal-title":"Oncotarget"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1182\/blood-2011-11-391474","article-title":"Whole Transcriptome Sequencing Reveals Recurrent NOTCH1 Mutations in Mantle Cell Lymphoma","volume":"119","author":"Kridel","year":"2012","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1182\/blood.V98.3.787","article-title":"Altered Apoptosis Pathways in Mantle Cell Lymphoma Detected by Oligonucleotide Microarray","volume":"98","author":"Hofmann","year":"2001","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"5142","DOI":"10.1182\/blood-2007-07-103481","article-title":"Distinct Functional Significance of Akt and mTOR Constitutive Activation in Mantle Cell Lymphoma","volume":"111","author":"Zancai","year":"2008","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"8090","DOI":"10.1200\/jco.2010.28.15_suppl.8090","article-title":"Correlation of Tumoricidal Activity of Lenalidomide against Hematologic Tumor Cells with Cyclin D1\/D2 Expression and Effect on Tumor-Suppressor Gene Upregulation","volume":"28","author":"Zhang","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2141.2009.07626.x","article-title":"Lenalidomide Oral Monotherapy Produces a High Response Rate in Patients with Relapsed or Refractory Mantle Cell Lymphoma","volume":"145","author":"Habermann","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nrd3937","article-title":"Targeting Pathological B Cell Receptor Signalling in Lymphoid Malignancies","volume":"12","author":"Young","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Tkachenko, A., Kupcova, K., and Havranek, O. (2023). B-Cell Receptor Signaling and Beyond: The Role of Ig\u03b1 (CD79a)\/Ig\u03b2 (CD79b) in Normal and Malignant B Cells. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25010010"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Profit\u00f3s-Pelej\u00e0, N., Santos, J.C., Mar\u00edn-Niebla, A., Rou\u00e9, G., and Ribeiro, M.L. (2022). Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas. Cancers, 14.","DOI":"10.3390\/cancers14040860"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood.2021011708","article-title":"Recurrent Splice Site Mutations Affect Key Diffuse Large B-Cell Lymphoma Genes","volume":"139","author":"Andrades","year":"2022","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2016-10-747303","article-title":"Tonic B-Cell Receptor Signaling in Diffuse Large B-Cell Lymphoma","volume":"130","author":"Havranek","year":"2017","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1182\/asheducation-2014.1.90","article-title":"Diagnosis of \u201cdouble Hit\u201d Diffuse Large B-Cell Lymphoma and B-Cell Lymphoma, Unclassifiable, with Features Intermediate between DLBCL and Burkitt Lymphoma: When and How, FISH versus IHC","volume":"2014","author":"Swerdlow","year":"2014","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood-2010-09-297879","article-title":"Double-Hit B-Cell Lymphomas","volume":"117","author":"Aukema","year":"2011","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/modpathol.2013.214","article-title":"Rearrangements of MYC Gene Facilitate Risk Stratification in Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP","volume":"27","author":"Tzankov","year":"2014","journal-title":"Mod. Pathol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/PAS.0b013e318244e2ba","article-title":"High Levels of Nuclear MYC Protein Predict the Presence of MYC Rearrangement in Diffuse Large B-Cell Lymphoma","volume":"36","author":"Green","year":"2012","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","article-title":"Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated with Rituximab plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone","volume":"30","author":"Johnson","year":"2012","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1182\/blood-2014-05-578963","article-title":"Impact of Induction Regimen and Stem Cell Transplantation on Outcomes in Double-Hit Lymphoma: A Multicenter Retrospective Analysis","volume":"124","author":"Petrich","year":"2014","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2009.26.3947","article-title":"Rearrangement of MYC Is Associated with Poor Prognosis in Patients with Diffuse Large B-Cell Lymphoma Treated in the Era of Rituximab","volume":"28","author":"Barrans","year":"2010","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1038\/leu.2008.230","article-title":"Structural Aberrations Affecting the MYC Locus Indicate a Poor Prognosis Independent of Clinical Risk Factors in Diffuse Large B-Cell Lymphomas Treated within Randomized Trials of the German High-Grade Non-Hodgkin\u2019s Lymphoma Study Group (DSHNHL)","volume":"22","author":"Klapper","year":"2008","journal-title":"Leukemia"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1182\/blood-2009-05-220095","article-title":"MYC Gene Rearrangements Are Associated with a Poor Prognosis in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP Chemotherapy","volume":"114","author":"Savage","year":"2009","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(13)60313-X","article-title":"Rituximab plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone in Patients with Newly Diagnosed Diffuse Large B-Cell Non-Hodgkin Lymphoma: A Phase 3 Comparison of Dose Intensification with 14-Day versus 21-Day Cycles","volume":"381","author":"Cunningham","year":"2013","journal-title":"Lancet"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1063689","DOI":"10.3389\/fonc.2022.1063689","article-title":"Comparison of Chemotherapy Regimens plus Rituximab in Adult Burkitt Lymphoma: A Single-Arm Meta-Analysis","volume":"12","author":"Lu","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/blood-2014-05-575092","article-title":"Primary Mediastinal B-Cell Lymphoma and Mediastinal Gray Zone Lymphoma: Do They Require a Unique Therapeutic Approach?","volume":"125","author":"Dunleavy","year":"2015","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1182\/blood-2023-190316","article-title":"Comparing Clinical Characteristics and Outcomes of MYC and BCL6 Double Hit Lymphoma (DHL-BCL6) with Other Aggressive B-Cell Lymphomas: Understanding the Impact of New Who and International Consensus Classifications","volume":"142","author":"Khurana","year":"2023","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1182\/blood-2023-173562","article-title":"Clinical Characteristics and Outcomes of Limited Stage High Grade B-Cell Lymphoma with MYC\/BCL2 and\/or BCL6 Rearrangements: A Single Center Experience","volume":"142","author":"Lue","year":"2023","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"4488","DOI":"10.1182\/blood-2023-188042","article-title":"Clinical and Molecular Features of Patients with Double\/Triple Hit Large B-Cell Lymphoma","volume":"142","author":"Shen","year":"2023","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1182\/blood-2017-12-820605","article-title":"High-Grade B-Cell Lymphoma with MYC and BCL2 and\/or BCL6 Rearrangements with Diffuse Large B-Cell Lymphoma Morphology","volume":"131","author":"Scott","year":"2018","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1200\/JCO.18.01583","article-title":"Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma","volume":"37","author":"Ennishi","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/hon.3098","article-title":"Cell of Origin Is Not Associated with Outcomes of Relapsed or Refractory Diffuse Large B Cell Lymphoma","volume":"41","author":"Desai","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/ejh.12589","article-title":"The Molecular Pathogenesis of B-cell non-Hodgkin Lymphoma","volume":"95","author":"Blombery","year":"2015","journal-title":"Eur. J. Haematol."}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2038-8330\/16\/1\/17\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:17:12Z","timestamp":1760105832000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/16\/1\/17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,21]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["hematolrep16010017"],"URL":"https:\/\/doi.org\/10.3390\/hematolrep16010017","relation":{},"ISSN":["2038-8330"],"issn-type":[{"type":"electronic","value":"2038-8330"}],"subject":[],"published":{"date-parts":[[2024,3,21]]}}}